Sign Up to like & get recommendations! 1
Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.390
Abstract: HLA-DQA1*05 Carriage is associated with development of anti-drug antibodies to infliximab in patients With Crohn’s Disease (Sazonovs et al. Gastroenterology 2019). Our group has shown that the presence of this allele is also an independent… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0037
Abstract: HLA-DQA1*05 carriage is associated with the development of anti-drug antibodies and loss of response (LOR) to tumour necrosis factor antagonists (anti-TNF) in patients with inflammatory bowel diseases (IBD)1. Ustekinumab has shown very low rates of… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.1027
Abstract: HLA-DQA1*05 carriage increases anti-tumour necrosis factor (TNF) immunogenicity and lowers drug persistence in European inflammatory bowel disease (IBD) patients. There is a paucity of data for Asian patients. We hypothesize that the HLA-DQA1*05 allele is… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.1403
Abstract: The development of Inflammatory Bowel Disease (IBD) appears to be related to genetic susceptibility and an excessive immune response of the intestinal mucosa. Tumour necrosis factor (anti-TNF) therapies are the most widely used biologic drugs… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000014454
Abstract: Background: Our previous studies demonstrate that the major histocompatibility complex (MHC) is associated with the progression of esophageal squamous cell carcinoma (ESCC). HLA-DQA1, which belongs to the MHC Class II family, may be a potential… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "International Journal of Immunogenetics"
DOI: 10.1111/iji.12696
Abstract: Carriage of HLA‐DQA1*05 is thought to increase the formation of anti‐tumour necrosis factor alpha (TNF‐α) antibodies, reducing the drug efficacy in Crohn's disease (CD) patients. However, little data are currently available for small‐bowel Crohn's disease… read more here.